Background
==========

Recent studies suggest infection and inflammation initiate certain cancers including cancers of the prostate \[[@B1]-[@B5]\]. According to the American Cancer Society, approximately 20% of all worldwide cancers are caused by infections \[[@B6]\]. These infectious agents may directly induce tumorigenesis through viral or bacterial protein products that have oncogenic effects or indirectly through a local chronic and progressive inflammatory response \[[@B7]-[@B9]\]. There is a paucity of information regarding the role of mucosal bacteria in contributing to malignancies of the prostate. One class of bacteria that is of particular interest is the *Mollicutes*. Mycoplasmas (class *Mollicutes*) are tiny, pleomorphic, wall-free, prokaryotic organisms that can reside either on the eukaryotic cell membrane or inside the cell. They are the smallest organisms (0.2-0.3 μm) capable of self-replication \[[@B10]\] with genomes of approximately 580-1200 kBp. Several mycoplasmas have been well documented as human pathogens \[[@B11],[@B12]\], however, it is conceivable that many mycoplasmal infections may go unidentified since numerous species can grow for extended periods of time in close interaction with mammalian cells without producing obvious cytopathic effects or noticeable symptoms.

A modern understanding of the latency of cancer and the emerging role of microbes in carcinogenesis raises the question of whether mycoplasmas can induce malignant transformation and thus warrants further investigation \[[@B13],[@B14]\]. Studies of leukemic patients in the mid-1960s raised the possibility of an association between mycoplasma infection and the development of leukemia \[[@B13]\]. Over the past several years much work has been devoted to identifying a mechanism by which mycoplasmas can transform cells. Specifically, our group reported that infection of benign human prostate cells, BPH-1, for 19 weeks resulted in anchorage-independent growth, increased migration and invasion, accumulation of chromosomal aberrations and polysomy, and the ability to form xenograft tumors in athymic mice. This was the first report describing the capacity of *M. hyorhinis*infection to cause the malignant transformation of benign human epithelial cells \[[@B15]\]. Furthermore, our group demonstrated that cells subjected to a single *M. hyorhinis*protein, p37, resulted in increased proliferation, significant genomic changes, and an enhanced invasive capability \[[@B16],[@B17]\].

Working independently, several groups have detected the *M. hyorhinis*p37 protein in cancer patients. The p37 protein was first described in an effort to identify human cell antigens that elicit tumor-specific antibodies. Fareed et al. \[[@B18]\] analyzed the immune response in a group of cancer patients who were immunized intralymphatically with tumor cell extracts. Sera samples from patients who were in a state of tumor regression showed measurable antibody titers against several antigens, including a 38-kDa protein. These antigens were not detected in those patients whose tumors failed to regress. The 38 kDa antigen was later identified as a mycoplasmal protein from *M. hyorhinis*. The protein was designated as p37 \[[@B19],[@B20]\]. In this study, we developed an indirect ELISA to investigate the presence of serum antibodies (IgG and IgM) against *M. hyorhinis*p37 in men with newly diagnosed localized prostate cancer.

Methods
=======

Patient Serum Specimens
-----------------------

After Institutional Review Board approval and signed informed consent, serum samples were prospectively collected from 321 men presenting to the Department of Urology University of Florida for evaluation of BPH or prostate cancer from 2006-2009. Briefly, 5-ml of whole blood was collected in a serum separating tube from each subject. Within 30 minutes, the tube was placed in the centrifuge and spun for 15 minutes at 2400 rpm as dictated in our standard operating procedures of our departmental tissue bank. Fifty microliter of serum was pipetted into multiple 1-ml cryogenic vials, snap-frozen and stored at -80°C for future use. Hospital records were reviewed for demographic, clinical and pathologic data. A total of 219 subjects (N = 114, BPH and N = 105, prostate cancer) with adequate hospital records and banked serum samples comprised the study cohort.

Expression and purification of recombinant p37
----------------------------------------------

*M. hyorhinis*p37 (MH38-113) was expressed and purified as previously described \[[@B16]\]. Briefly, plasmids were transformed into BL21(DE3)pLysS E. coli cells. The transformation was used to inoculate 1-L LB media with 100 mg L21 ampicillin and cultured at 37°C until the OD 600 nm was 0.7-1.0. Cells were induced using 1 mL of 1M isopropyl b-D-1 thiogalactopyranoside and allowed to express for three hours. Cells were lysed by vortexing the pellet in 1/10 the original volume of 20 mmol/L phosphate buffer (pH 7.8) followed by a sonication for three 15-second cycles. The resulting crude cell lysate was centrifuged at 40,000 × g for 20 minutes at 4°C to remove cell debris. The clear supernatant (soluble cellular extract) was subjected to ion exchange chromatography using the Econo System (Bio-Rad). A 5 mL Bio-Rad Econo-Pac S cation exchange column was attached to the bottom of a 50 mL Bio-Rad anion exchange Q column, and equilibrated with 20 mmol/L sodium phosphate buffer (pH 7.95) at a flow rate of 2.5 mL/min. Approximately 125 mg of soluble cellular extract were loaded on the column. The flow-through containing *M. hyorhinis*p37 was adjusted to pH 6.1 with 2 mol/L acetic acid, and loaded on a 5 mL cation exchanger, Bio-Rad Econo-Pac S cartridge, equilibrated with 20 mmol/L sodium acetate, pH 6.1 (buffer A). The column was washed with 5% buffer B \[20 mmol/L sodium acetate (pH 6.1), 1 mol/L NaCl\] and the *M. hyorhinis*p37 protein was eluted with 15% buffer B. The eluted sample was then concentrated using a Centriprep 10 spin column (Millipore, Bedford MA). Purity was confirmed by 10% SDS-PAGE stained with Coomassie Blue (Figure [1](#F1){ref-type="fig"}). Concentrations were calculated by absorbance at 280 nm using a calculated extinction coefficient of 54,620 M^-1^cm^-1^.

![**Purification of recombinant *M. hyorhinis*p37 protein by affinity chromotography**. *M. hyorhinis*p37 (MH38-113) was expressed in *E. coli*and purified as described previously \[[@B16]\]. Sonicated cell lysate of *E. coli*was applied to a cobalt affinity column, and the bound protein was eluted with 150 mM imidazole. A total of 25 μg eluate was electrophoresed in a 12% SDS-PAGE gel, and stained with Coomassie blue. M, Prestained BenchMark Protein ladder (kDa); 1, purified recombinant protein. The arrow indicates the position of the recombinant protein.](1471-2407-11-233-1){#F1}

Indirect ELISA
--------------

A 96-well plate was coated with 100 μl of diluted *M. hyorhinis*p37 (0.5 μg/well). Plates were incubated for at least one hour at room temperature. The plate was washed four times with TBS/Tween 20 (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 5 mM MgCl2, 0.5 mM CaCl2, 0.05% (v/v) Tween 20. Next, the plates were blocked with 300 μl of TBS/1% BSA and incubated for 1 hour. Again the plates were washed as described above. Based on our preliminary studies (data not shown), thawed human sera samples were diluted 1/100 with TBS and 100 μl of each diluted human sera were then added to the 96-well plate in duplicate. Plates were incubated for another one hour at room temperature. Plates were washed four times as described previously followed by the addition of 100 μl of diluted anti-human antibody (1/100) conjugated to alkaline phosphatase. Plates were incubated for one hour at room temperature then washed again. Next, the plate was washed once with TBS containing no Tween 20, and 100 μl of freshly made p-NPP in development buffer was added.

We used a naturally occurring antibody as an internal control. The disaccharide, Gal1α1,3 Gal, is present in all humans, and IgG antibodies to Gal1α1,3 Gal are found to be present in high titers in the serum of every normal individual, and are constantly produced throughout life \[[@B21]\]. Gal1α1,3 Gal was purchased from Sigma Chemical Co., St. Louis, Missouri, USA. Test serum samples were also assayed with Galα1,3 Gal as the substrate (positive control) coupled to bovine serum albumin (BSA). BSA alone served as the negative control. Plates were read at 405 nm in a plate reader. All of the sera tested showed a strong positive response against Galα1,3 Gal-BSA and no response to BSA alone (data not shown).

Statistical analysis
--------------------

We used the Wilcoxon rank-sum test to compare the O.D. values and PSA values in the prostate cancer group to those in the BPH group. Since we are testing the hypothesis that the O.D. values and PSA values in the prostate cancer group are higher than that in the BPH group, all reported *p*-values are one-sided. The one-sided Wilcoxon rank-sum test is also used to assess the correlation between O.D. values and clinical parameters. We defined a diagnostic test (positive indirect ELISA assay vs. negative indirect ELISA assay) using a cutoff value of O.D. selected to maximize the sum of the sensitivity and specificity of the test \[[@B22]\]. All data analyses were performed using SAS software version 9.1.3.

Results
=======

Sera from a total of 219 subjects (N = 114, BPH and N = 105, prostate cancer) comprised our study cohort. The cohorts\' demographic, clinical and pathologic features are summarized in Table [1](#T1){ref-type="table"}. The two study groups (BPH and prostate cancer) were well matched for age and race. Serum PSAs were higher in the cancer group versus the BPH group (5.7 [+]{.ul}5.1 vs. 0.9[+]{.ul}1.8, *p*\< 0.0001). Of the 105 subjects with prostate cancer, the majority of subjects presented with low risk prostate cancer; clinical T1c prostate cancer (69%), serum PSA [\<]{.ul}10 ng/ml (86%) and Gleason score 3+3 = 6 (65%). A small percentage of these subjects (n = 38) underwent a radical prostatectomy for definitive therapy. Table [2](#T2){ref-type="table"} describes clinicopathologic features of the prostatectomy cohort. Median follow-up of our entire cohort was 18.1 months. In this short follow-up, 5% of the patients experienced biochemical recurrence.

###### 

Demographic and clinicopathologic characteristics of study cohort

                             BPH              Cancer
  -------------------------- ---------------- ------------
                             N = 114          N = 105
  Median Age (range, y)      60 (30-86)       60 (41-79)
  Race                                        
   White                     73 (64)          72 (69)
   African American          30 (26)          17 (16)
   Other                     11 (10)          16 (15)
  Median Serum PSA (ng/ml)   0.9[+]{.ul}1.8   5.7 ± 5.1
  Clinical Stage                              
  T1c                        n/a              74 (70%)
  T2a                        n/a              26 (25%)
  T2b                        n/a              1 (1%)
  T2c                        n/a              2 (2%)
  T3a/b                      n/a              1 (1%)
  T2aNxM1                    n/a              1 (1%)
  Gleason Score                               
  6                          n/a              68 (65%)
  7                          n/a              23 (22%)
  \>7                        n/a              14 (13%)

###### 

Demographic and clinicopathologic characteristics of 38 study subjects who underwent radical prostatectomy

                             Cancer
  -------------------------- ------------
                             N = 38
  Median Age (range, y)      63 (47-72)
  Race                       
   White                     24 (63)
   African American          12 (32)
   Other                     2 (5)
  Median Serum PSA (ng/ml)   9.2 ± 4.7
  Pathologic Stage           
  pT2                        31 (82%)
  pT3a                       3 (8%)
  pT3b                       4 (10%)
  N0                         36 (95%)
  N1                         2 (5%)
  Gleason Score              
  6                          19 (50%)
  7                          13 (34%)
  \>7                        6 (16%)

Indirect ELISA assays were performed on all 219 sera samples in duplicate. The median O.D. value for the BPH group was 0.31 whereas the median O.D. value was 0.35 in the prostate cancer group (*p*= 0.035). The distributions of O. D. values are presented in a box plot (Figure [2](#F2){ref-type="fig"}). Through further data analysis we determined an optimum O.D. cut off value to distinguish a positive indirect ELISA assay (i.e., harboring antibodies to *M. hyorhinis*p37) of \> 0.348. Utilizing this O.D. cut off value, 41 out of the 114 (36%) BPH subjects and 55 of 105 (52%) prostate cancer subjects had antibodies to *M. hyorhinis*p37 (*p*= 0.014) (Table [3](#T3){ref-type="table"}). Figure [3](#F3){ref-type="fig"} depicts the sensitivity of this novel indirect ELISA assay towards *M. hyorhinis*p37 antibodies. The O.D. values were not significantly associated with clinical stage of prostate cancer patients (*p*= 0.39). The O.D. values of prostate cancer patients with Gleason score 7 or higher were significantly higher than that with Gleason score 6 (*p*= 0.016). Biochemical recurrence was not associated with a positive ELISA assay (*p*\> 0.05).

![**Box plots of O.D. value detecting *M hyorhinis*serum antibodies**. The distributions of O. D. values are presented in a box plot.](1471-2407-11-233-2){#F2}

###### 

Summary of serum Ig *M.hyorhinis*p37 antibody detection by Indirect ELISA

                              -Ig Mh         \+ Ig Mh       *p*-value
  --------------------------- -------------- -------------- -----------
  Benign Patients (N = 114)   73/114 (64%)   41/114 (36%)   0.014
  Cancer Patients (N = 105)   50/105 (48%)   55/105 (52%)   

![**Detection limits of novel indirect ELISA for *M. hyorhinis*serum antibodies**. Varying concentrations of *M. hyorhinis*antibodies were added to our indirect ELISA to illustrate the range of detection.](1471-2407-11-233-3){#F3}

Discussion
==========

In this study, we provide evidence supporting a potential role for mycoplasma in the initiation and/or propagation of human cancers. Fifty-two percent of men with prostate cancer harbored antibodies to *M. hyorhinis*while only thirty-six percent of men with the benign prostate condition, BPH, were found to have antibodies to *M. hyorhinis (p*= 0.014). If antibodies to *M. hyorhinis*are present, then we assume that these individuals were exposed to *M. hyorhinis*within their life time. This is not unexpected since *M. hyorhinis*is a ubiquitous organism. Other intriguing links between cancer and *M. hyorhinis*exposure have been recently elucidated. A group from Japan reported that 48% of tumors from patients with gastric cancer were positive for *M. hyorhinis*\[[@B23]\]. In addition, a study from China strongly supports a link between *M. hyorhinis*, p37 expression and cancer. A monoclonal antibody that specifically recognizes p37 was used to test for reactivity in over 500 paraffin-embedded normal and diseased tissues. The results indicated that 40-53% of gastric, esophageal, and colon carcinoma samples were positive for reactivity with the *M. hyorhinis*p37 monoclonal antibody \[[@B24]\].

Our laboratory has preliminary evidence linking *M. hyorhinis*protein p37 to cancer initiation and/or progression \[[@B16],[@B17]\]. Specifically we demonstrated that recombinant p37 enhanced the invasiveness of two prostate carcinoma and two melanoma cell lines in a dose-dependent manner *in vitro*, but did not have a significant effect on tumor cell growth. These findings could be completely blocked with a neutralizing antibody to *M. hyorhinis*p37 \[[@B16]\]. In a separate study, recombinant *M. hyorhinis*p37 induced a more malignant phenotype in prostate cancer cells PC-3 and DU145 as demonstrated by significant nuclear enlargement, anaplasia, and increased migratory activity. Furthermore, these cells showed differential expression of genes involved in cell cycle, signal transduction and metabolism \[[@B17]\]. Taken together, these studies support a strong association between *M. hyorhinis*p37 epitope expression and cancer that is complex, probably requiring a long latency period, and may be dependent upon specific host factors.

Mycoplasmas are notorious for producing infections that can persist for up to a year or longer \[[@B25]\]. The effects of long-term exposure of mycoplasma on gene expression in mammalian cells have been carefully studied \[[@B26]\]. Gene expression changes were examined following infection of human cervical and prostatic epithelial cells *in vitro*with a panel of mycoplasmas. The changes in expression of 38 key cytokine genes were examined over a period of time ranging from 12 hours to 36 weeks. The results indicated that, even in the absence of apparent changes in cell growth or cell morphology, mycoplasmal infections rapidly altered the expression of many key genes, thus altering numerous important biological functions within cells \[[@B26]\].

Over the past several years much work has been devoted to identifying a mechanism by which mycoplasmas can transform cells. The oncogenic potential of human mycoplasmas, *M. fermentans*and *M. penetrans*, were studied using cultured C3H mouse embryo cells \[[@B27]\]. Transformation with mycoplasma was a multistage process, with distinct phases in promotion and progression towards malignancy. During initial mycoplasmal infection, the effects were reversible (i.e., removal of the mycoplasma restored normal cellular function). However, after chronic infection, the transformation became irreversible. Thus, mycoplasma-mediated oncogenesis had a long latency period and required a chronic persistent infection, as opposed to the acute transformation induced by most oncogenic viruses \[[@B26]\]. Because of this long latency, it is extremely difficult to establish a link between mycoplasmas and cancer through an epidemiologic approach.

Our group has studied the oncogenic potential of *M. hyorhinis*using cultured BPH-1, benign human prostate cells. The immortalized BPH-1 cell line was derived from primary cultures of benign prostatic epithelial cells by introducing SV40T antigen \[[@B28]\] which inactivates both p53 and Rb tumor suppressor genes. Thus we hypothesized that further insult or stress (e.g., chronic mycoplasmal exposure) in these benign prostate cells may render the benign cells susceptible to further genetic damage and to progression along a pathway to malignancy. After being exposed to *M. hyorhinis*for 19 weeks, BPH-1 cells achieved anchorage-independent growth, increased migration and invasion, accumulation of chromosomal aberrations and polysomy and formed xenograft tumors in athymic mice. Transformation with mycoplasma was a multistage process, with distinct phases in promotion and progression towards malignancy \[[@B15]\]. This novel cell transformation model was critical in elucidating the potential of chronic mycoplasmal exposure leading to the development of prostate cancer. Though intriguing, further work is needed to confirm and further explain the role of *M. hyorhinis*in the development and propagation of human prostate cancer.

We report the development of the first indirect ELISA assay for the detection of circulating *M. hyorhinis*antibodies in human serum samples. Overall, *M. hyorhinis*antibody was detected in 44% of our cohort (36% in BPH and 52% in prostate cancer). The percent of IgG and IgM antibodies within the entire pool of antibodies were not determined, neither were antibody titers, however, we did find this system of detecting *M. hyorhinis*antibodies to be reliable and simple, thus allowing further evaluation of this assay in subjects with prostate cancer.

Overall this study provides strong evidence that humans are exposed to *M. hyorhinis*and such exposure may be associated with the development of certain cancers. We recognize that numerous limitations are evident in the current study. First, this is a small, highly selected cohort and thus may not represent the average BPH or prostate cancer patient. Second, confirmation of *M. hyorhinis*within the prostate via immunohistochemical staining or a similar assay was not performed due to limitations of high-quality antibodies directed at *M. hyorhinis*. Third, the association between mycoplasma and prostate cancer is complex and may require a long latency period, a specific set of host attributes, or possibly exposure to a particular strain of mycoplasma, none of these have been clearly identified. Fourth, we do not believe *M. hyorhinis*itself causes malignant transformation, but when present it may further stress cells that have the propensity to become malignant as was evident in our preclinical study \[[@B15]\]. Fifth, our control group was comprised of men with BPH, a benign overgrowth of the prostate. Though it would be ideal to have as a control men without this benign overgrowth of the prostate it is not feasible seeing that the majority of elderly men will have BPH.

We have demonstrated an increased rate of seropositivity to *M. hyorhinis*in men with prostate cancer (52%) compared to men with BPH (36%) presenting to an outpatient Urology clinic, thus providing the first correlation of mycoplasmal exposure and prostate cancer. Though a significant percentage of men with BPH harbored antibodies to *M. hyorhinis*p37, we still believe we have a valid hypothesis. First, *M. hyorhinis*is ubiquitously found in the environment. Second, we believe that prostatic tissue may be exposed to *M. hyorhinis*, which can cause a chronic inflammatory milieu leading to cellular changes. This effect may be instigated by the cell surface protein p37 directly. These cellular changes, when coupled with other cellular stressors, can induce malignant transformation. Thus, it is not surprising to find *M. hyorhinis*in significant proportion of subjects with a benign condition.

Conclusions
===========

Our current findings coupled with our previous findings of how mycoplasma can transform benign prostatic cells have led us to hypothesize that mycoplasmal exposure may be linked to the initiation and propagation of some prostate cancers. Further epidemiologic studies into this phenomenon are required, but the idea that mycoplasmas can exacerbate, or perhaps even initiate human prostate malignancy may stimulate new thinking on how we prevent, diagnose and treat prostate cancers.
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